Stock Events

Stock Events

Grace Therapeutics 

$2.38
139
+$0.01+0.42% Friday 20:00
+$0.00+0%Friday 20:00After hours

Statistics

Day High
2.37
Day Low
2.36
52W High
5.18
52W Low
1.79
Volume
3,350
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.37
-0.21
-0.05
0.11
Expected EPS
-0.1293
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
0Revenue
-12.85MNet Income

Analyst Ratings

8.00Average Price Target
The highest estimate is 8.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GRCE. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Amarin
AMRN
Mkt Cap336.13M
Amarin Corporation plc focuses on the development and commercialization of therapeutics for cardiovascular health, directly competing with Acasti Pharma's focus on omega-3 phospholipids for similar conditions.
Astrazeneca
AZN
Mkt Cap292.2B
AstraZeneca PLC, a large pharmaceutical company, has a diverse portfolio that includes treatments for cardiovascular diseases, competing with Acasti Pharma's cardiovascular focus.
Pfizer
PFE
Mkt Cap138.44B
Pfizer Inc. has a broad range of products including treatments for cardiovascular diseases, making it a competitor to Acasti Pharma in the cardiovascular therapeutic area.
Merck
MRK
Mkt Cap317.77B
Merck & Co., Inc. offers a wide range of healthcare solutions, including cardiovascular disease treatments, competing with Acasti Pharma's product offerings.
Novartis
NVS
Mkt Cap296.54B
Novartis AG, with its extensive research and development in cardiovascular diseases, competes with Acasti Pharma in the market for cardiovascular health solutions.
GSK
GSK
Mkt Cap105.17B
GlaxoSmithKline plc has a diversified portfolio that includes cardiovascular drugs, making it a competitor to Acasti Pharma in the cardiovascular space.
Abbvie
ABBV
Mkt Cap447.62B
AbbVie Inc. engages in the discovery, development, manufacture, and sale of a broad line of pharmaceuticals, including those for cardiovascular diseases, competing with Acasti Pharma.
AMGEN
AMGN
Mkt Cap193.39B
Amgen Inc. focuses on human therapeutics, including cardiovascular disease treatments, which positions it as a competitor to Acasti Pharma.
Bristol-Myers Squibb
BMY
Mkt Cap117.46B
Bristol-Myers Squibb Company offers a wide range of prescription pharmaceuticals in several therapeutic areas, including cardiovascular diseases, competing with Acasti Pharma's focus.

About

Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
Show more...
CEO
Mr. Prashant Kohli
Employees
4
Country
United States
ISIN
US00439U1043

Listings

F
DE
A1P0.F
STU
DE
L8S.STU
XNAS
US
GRCE
F
DE
L8S.F

0 Comments

Share your thoughts

FAQ

What is Grace Therapeutics stock price today?▼
The current price of GRCE is $2.38 USD — it has increased by +0.42% in the past 24 hours. Watch Grace Therapeutics stock price performance more closely on the chart.
What is Grace Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Grace Therapeutics stocks are traded under the ticker GRCE.
Is Grace Therapeutics stock price growing?▼
GRCE stock has risen by +5.31% compared to the previous week, the month change is a -7.39% fall, over the last year Grace Therapeutics has showed a -19.87% decrease.
When is the next Grace Therapeutics earnings date?▼
Grace Therapeutics is going to release the next earnings report on August 06, 2026.
What were Grace Therapeutics earnings last quarter?▼
GRCE earnings for the last quarter are -0.14 USD per share, whereas the estimation was -0.28 USD resulting in a +50% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Grace Therapeutics revenue for the last year?▼
Grace Therapeutics revenue for the last year amounts to 0 USD.
What is Grace Therapeutics net income for the last year?▼
GRCE net income for the last year is -12.85M USD.
How many employees does Grace Therapeutics have?▼
As of June 29, 2026, the company has 4 employees.
In which sector is Grace Therapeutics located?▼
Grace Therapeutics operates in the Health & Wellness sector.
When did Grace Therapeutics complete a stock split?▼
The last stock split for Grace Therapeutics was on July 10, 2023 with a ratio of 1:6.
Where is Grace Therapeutics headquartered?▼
Grace Therapeutics is headquartered in Princeton, United States.